Cell & Gene

Cell & Gene operates under Life Science Connect, which helps create connections and encourages partnerships within the pharmaceutical, biotech, and medical device sectors. They achieve this through various channels, including online platforms, publications, events, and training programs.

International, Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#726680

United States

#262119

Health/Biotechnology and Pharmaceuticals

#239

Traffic sources

Monthly visitors

Articles

One Stone, Two Birds: Engineering Rep-Cap Plasmids To Enhance AAV Manufacturability And Potency

3 days ago | cellandgene.com | Xiaojun Liu |Yeonji Kim |Chris Brown |Jing Zhu

By Xiaojun Liu, Yeonji Kim, Chris Brown, and Jing Zhu Recombinant adeno-associated virus (rAAV) vectors are pivotal in gene therapy due to their proven safety and efficacy for therapeutic gene delivery. However, low production yields and vector heterogeneity remain significant barriers to scalable, high-quality manufacturing.
05.27.25 -- Ferring Builds A Global Gene Therapy Manufacturing Network Around ADSTILADRIN

1 week ago | cellandgene.com | Erin Harris |Todd Andrews |James Calle |Matt Dean

Webinar: Advanced Contamination Control for Cell Therapy: Automation, Assays, and Process EfficiencyThis webinar explores contamination control in cell therapy manufacturing, focusing on automated closed systems, larger bioprocess containers, and rapid analytical assays. It highlights how these tools enhance sterility, efficiency, and product quality. Experts Alexandra Lisi and Sandi True will share insights into integrating these solutions for improved operational effectiveness.
Unlocking The Potential Of iPSC Therapies In Regenerative Medicine

2 weeks ago | cellandgene.com | Erin Harris

By Erin Harris, Editor-In-Chief, Cell & Gene Follow Me On Twitter @ErinHarris_1 During our most recent Cell & Gene Live, Unlocking the Potential of iPSC Therapies in Regenerative Medicine, I had the privilege of moderating a conversation with two pioneering leaders shaping the future of regenerative medicine: Julie Allickson, Ph.D., Chief Technology Officer at Mayo Clinic's Center for Regenerative Biotherapeutics and Erin Kimbrel, Ph.D., Head of Cell & Gene Therapy Research at Astellas.
Ferring Builds a Global Gene Therapy Manufacturing Network Around ADSTILADRIN

3 weeks ago | cellandgene.com | Erin Harris

By Erin Harris, Editor-In-Chief, Cell & Gene Follow Me On Twitter @ErinHarris_1 As gene therapy continues to redefine what’s possible in the treatment of serious diseases, the commercial challenges that accompany this modality are becoming just as critical to address as the science itself.
05.15.25 -- Pharmaceutical Sovereignty: The Resilience We Cannot Outsource

3 weeks ago | cellandgene.com | ajaz Hussain |Junwei Sun |Lucia Fernandez |Lucia Fernández |Matthew Ercolino

Pharmaceutical sovereignty is no longer a theoretical concern. Sovereignty in this context does not imply isolation, but rather strategic resilience: building robust national and regional capabilities that ensure security while enabling global collaboration. Utilizing Quantitative PCR For The Assessment Of AAV SheddingExplore AAV shedding assessment using qPCR, featuring experts discussing assay development, monitoring challenges, and ensuring safety in clinical studies.
Atsena Therapeutics Advances Gene Therapy For XLRS

3 weeks ago | cellandgene.com | Erin Harris

By Erin Harris, Editor-In-Chief, Cell & Gene Follow Me On Twitter @ErinHarris_1 While the CGT sector has made significant strides in oncology, its transformative potential extends well beyond cancer. A growing number of companies are advancing CGT approaches for rare and inherited diseases, including those affecting vision.
05.01.25 -- Navigating CGT Biotech's Financial Headwinds And The Path Forward

1 month ago | cellandgene.com | Erin Harris

Discover the future of iPSC-based therapies in this free Cell & Gene Live digital event. Experts will share insights on emerging applications, regulatory challenges, gene editing advancements, and key safety considerations in scalable iPSC manufacturing. Don't miss this opportunity to hear from leaders at the forefront of regenerative medicine. Supported by Invetech.
04.28.25 -- Navigating Tariffs: Implications And Strategies For Pharmaceuticals Manufacturers

1 month ago | cellandgene.com | Nero Haralalka |Junwei Sun |Lucia Fernandez |Lucia Fernández |Matthew Ercolino

The ISCT 2025 Scientific Annual Meeting (May 7-10 in New Orleans) is the largest global gathering for KOLs and subject matter experts for driving the clinical translation of cell and gene therapies. The work presented at this conference spans regulatory affairs, workforce development and the entire development pathway from pre-clinical work to Phase 3 clinical trials, CGT product launch and market access.
04.25.25 -- Why You Need A Raw Material Control Strategy

1 month ago | cellandgene.com | Christina Bennett |Joe Cintavey |W.L. Gore |Sanjeev Luther

Transforming the Biopharma Supply Chain, eData Solutions for Agility and Manufacturing EfficiencyWatch our engaging webinar to discover how eData empowers biopharma supply chains with process automation, critical analytics, and predictive logistics. Learn how manufacturers can proactively mitigate disruptions and adopt a standardized digital platform for resilient operations here. You should start with the end goal in mind, but the first draft is almost never the last.
04.24.25 -- How Cynata Therapeutics Is Unlocking The Power Of iPSCs To Transform Regenerative Medicine

1 month ago | cellandgene.com | Erin Harris |Dan Nelson |CARR Biosystems |Royce Tourtillott

Setting the Standard in CGT: Perspectives on Performance, Scalability, and Regulatory ComplianceExplore the evolving landscape of cell and gene therapy with insights from key opinion leaders. This white paper addresses challenges in process development and manufacturing across different modalities. Discover how end-to-end solutions can accelerate commercialization by prioritizing performance and scalability while simplifying the path to regulatory approvals.